MTOR and neoplasm: Given the immunologically “cold” nature of pediatric HGGs and DMGs - characterized by low levels of T cells - rationally combining the immunostimulatory effects of PI3K/mTOR inhibitors with ICIs or CAR T cells may represent a critical avenue to overcome resistance and drive more durable anti-tumor responses.